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Abstract

Background In a phase II North American study
(NP28761; NCT01871805), the anaplastic lymphoma
kinase (ALK) inhibitor alectinib demonstrated both
systemic and central nervous system (CNS) efficacy with
good tolerability in patients with ALK-positive non-small
cell lung cancer. We describe patient-reported outcomes
(PROs) from the NP28761 study.
Patients and methods PROs and health-related quality
of life (HRQoL) benefits were assessed using two selfadministered questionnaires (the European Organisation
for Research and Treatment of Cancer 30-Item Quality
of Life Questionnaire-Core (EORTC QLQ-C30), and the
13-item EORTC QLQ-lung cancer-specific module) at
enrolment and every 6 weeks until week 66, disease
progression or death.
Results Clinically meaningful mean improvements
(≥10 point change from baseline) were observed in 10
domains, including global health status (GHS), role and
social functioning, fatigue, pain, dyspnoea, and appetite
loss. A clinically meaningful improvement was observed
in GHS from the first assessment (6 weeks) until week 60.
Alectinib demonstrated a rapid effect, with a median time
to symptom improvement, using the composite endpoint
of cough, dyspnoea and pain in the chest, of 1.4 months
(6.1 weeks) (95% CI 1.4 to 1.6) and a median time to
symptom deterioration of 5.1 months (22.1 weeks) (95% CI
2.8 to 6.8). Patients with CNS metastases at baseline
experienced comparable HRQoL over the duration of the
study as patients without CNS metastases. Exploratory
analysis showed that the occurrence of an objective
response may be associated with a better HRQoL.
Conclusions Patients treated with alectinib in this phase
II study achieved clinically meaningful improvements in
HRQoL and symptoms and had delayed time to symptom
deterioration.

Introduction
Non-small cell lung cancer (NSCLC) is
the most common subtype of lung cancer,
accounting for around 80%–85% of all cases.
In the majority of patients, the disease has
reached an advanced stage by the time of

Key questions
What is already known about this subject?
►► Alectinib has shown promising systemic and central

nervous system (CNS) efficacy in the treatment of
patients with anaplastic lymphoma kinase-positive
(ALK+) non-small cell lung cancer (NSCLC) who
were previously treated with crizotinib, and is well
tolerated.
►► Additionally, alectinib has now demonstrated significantly superior efficacy compared with crizotinib
in patients with advanced treatment-naïve ALK+
NSCLC.

What does this study add?
►► This current analysis is the first to demonstrate that

alectinib can both improve patient-reported symptom burden and enhance health-related quality of
life (HRQoL).
►► The median time to patient-reported outcome (PRO)
symptom improvement with alectinib was 1.4
months (95% CI 1.4 to 1.6).
►► Baseline CNS metastases did not impact HRQoL
over the duration of the study.

How might this impact on clinical practice?
►► Patients treated with alectinib in the North American

NP28761 study reported clinically meaningful
improvement in key lung cancer symptoms, patient-reported function and HRQoL while remaining
a tolerable treatment option.
►► These PRO data are consistent with the safety data
previously reported and confirm the tolerability of
alectinib in patients with ALK+ NSCLC who were
previously treated with crizotinib.

diagnosis1 and often results in substantial
symptom burden (eg, fatigue, dyspnoea,
cough and pain).2 While more conventional
anticancer therapies, such as chemotherapy,
provide a marginal improvement in overall
survival, the side effects are often significant, which may overshadow the treatment

Ou S-HI, et al. ESMO Open 2018;3:e000364. doi:10.1136/esmoopen-2018-000364

1

Open access
benefits. This can be detrimental to a patient’s health-related quality of life (HRQoL), impacting physical,
emotional and social functioning. Hence, many clinical
trials now include patients’ self-ratings on the impact of
disease treatment on symptoms, functioning and HRQoL
(collectively referred to as patient-reported outcomes
(PRO)) as study endpoints to inform the assessment of
clinical benefit.
Anaplastic lymphoma kinase-positive NSCLC (ALK-positive NSCLC) is a distinct subset of lung cancer which is
characterised by rearrangements of the ALK gene. The
current standard of care for ALK-positive NSCLC is the
ALK tyrosine kinase inhibitor (TKI) crizotinib, which
has demonstrated improved response rates and HRQoL
compared with chemotherapy.3 4 However, progression
usually occurs within 1 year of treatment on crizotinib,
with the most common site of progression being the
central nervous system (CNS).
Alectinib is an oral ALK TKI which has demonstrated
efficacy for patients with ALK-positive NSCLC, both
systemically and in the CNS.5–9 In the single-arm, phase II,
North American study of alectinib in ALK-positive NSCLC
in patients who were previously treated with crizotinib
(NP28761; NCT01871805), at the April 2015 data cut-off,
an objective response rate (ORR) of 52.2% (n=35/67)
was reported in patients with measurable disease at baseline according to the independent review committee
(IRC), with a median progression-free survival of 8.1
months (95% CI 6.2 to 12.6) and a median duration of
response (DOR) of 13.5 months (95% CI 6.7 to not estimable). In patients with measurable CNS metastases at
baseline, alectinib demonstrated a CNS ORR of 75.0%
(95% CI 47.6 to 92.7) and a CNS DOR of 11.1 months
(95% CI 5.8 to 11.1). Here, we summarise the PRO data
from this study.

Patients and methods
Study design and patients
The design of the NP28761 study has been published
previously.7 Briefly, this was a single-arm, multicentre
study. Eligible patients were aged ≥18 years, with locally
advanced or metastatic (stage IIIB–IV) ALK-positive
NSCLC, which was confirmed by a US Food and Drug
Administration-approved fluorescent in situ hybridisation test, and an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0–2. Patients had
progressed on crizotinib. Baseline CNS metastases were
permitted, providing they were asymptomatic.
Patients received 600 mg of oral alectinib twice daily.
The primary endpoint of the study was ORR according to
the Response Evaluation Criteria in Solid Tumours V.1.1
as assessed by an IRC. HRQoL, as measured by the global
health status (GHS) scale of the European Organisation
for Research and Treatment of Cancer 30-Item Quality
of Life Questionnaire-Core (EORTC QLQ-C30), was
defined as the secondary endpoint.
2

The study was undertaken in accordance with the
principles of the Declaration of Helsinki, and written
informed consent was obtained from all patients.
Patient-completed questionnaires
Patient-reported symptoms and HRQoL were assessed
using two self-administered questionnaires that have been
routinely used to describe PROs in lung cancer studies.4 10
The first questionnaire is the EORTC QLQ-C30,11 which
comprises 30 questions across five functional scales
(physical, role, social, cognitive and emotional), a GHS
scale, three symptom scales (fatigue, pain and nausea/
vomiting) and various single-item symptom scales. The
second questionnaire is the EORTC QLQ-lung cancer-specific module (EORTC QLQ-LC13),12 which comprises
13 questions assessing lung cancer-specific symptoms,
including cough, dyspnoea, pain in the chest and others.
Data were collected at randomisation and every 6 weeks
until week 66, disease progression or death.
Statistical analyses
Questionnaire items were scored according to the EORTC
algorithms,13 which standardise the raw score to a range
of 0–100. For the functional scales and GHS items, a
higher score represents a better level of functioning. For
each of the symptom scales, a lower score represents a
lower level of that particular symptom (ie, lower symptom
burden). The mean change from baseline analyses
was documented for all subscales, with a 10-point change
considered to be clinically meaningful.14 15 The time to
symptom deterioration or improvement was defined as
the time from randomisation to the first appearance of
a score ≥10 points worse or better than baseline, respectively, and was assessed for the symptoms of cough, dyspnoea or pain in the chest using the QLQ-LC13 scale.14
The time to symptom deterioration or improvement
was summarised using the Kaplan-Meier methodology,
without imputation of missing baseline values. Symptom
deterioration was also examined for patients with and
without baseline CNS metastases. Multiple exploratory
analyses were conducted to understand the patient-reported benefit of alectinib’s CNS activity, including the
relationship between best overall response (complete or
partial) and emotional functioning and cognitive functioning. In addition, a comparison of baseline ECOG PS
and PRO scores was done to evaluate differences in these
subgroups.

Results
Patients
In total, 87 patients were enrolled between 4 September
2013 and 4 August 2014. The median age of patients was
54 years (range 29–79), 45% of patients were male, 90%
had an ECOG PS of 0 or 1, and 84% of patients were
white. At baseline, 60% (52/87) of patients had measurable and/or non-measurable CNS metastases.
Ou S-HI, et al. ESMO Open 2018;3:e000364. doi:10.1136/esmoopen-2018-000364
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Table 1 Baseline, week 6 and mean change from baseline values for the QLQ-C30 and QLQ-LC13
Baseline
Baseline mean±SD median

Week
6 mean±SD

Week
6 median

Mean change from Median change
baseline±SD
from baseline

Global health status
(QLQ-C30)
Functioning (QLQ-C30)

53.59±24.27

58.33

71.94±20.05

75.00

15.89±25.66

16.67

 Physical

69.96±24.43

73.33

76.18±20.19

80.00

4.69±17.44

0.00

 Social

60.55±35.32

66.67

75.98±25.85

83.33

11.20±23.20

0.00

 Role

58.86±34.06

66.67

76.72±27.34

83.33

14.84±32.00

0.00

 Cognitive

77.85±24.13

83.33

81.62±24.63

83.33

2.34±20.76

0.00

 Emotional

73.49±21.40

75.00

81.13±19.03

83.33

7.99±18.75

8.33

 Fatigue

45.57±27.02

44.44

33.33±24.13

33.33

–10.94±25.70

–11.11

 Nausea and vomiting

15.61±20.73

0.00

7.84±17.15

0.00

–6.77±19.63

0.00

 Pain

36.29±33.63

33.33

22.30±26.95

16.67

–12.50±33.47

0.00

 Dyspnoea

33.33±30.86

33.33

22.55±24.73

33.33

–12.17±32.96

0.00

 Insomnia

31.22±30.82

33.33

22.06±25.50

33.33

–9.38±29.38

0.00

 Appetite loss

29.96±33.16

33.33

11.76±23.58

0.00

–16.67±30.28

0.00

 Constipation

20.25±26.38

0.00

27.45±29.89

33.33

9.90±30.68

0.00

 Diarrhoea

13.25±23.01

0.00

4.90±15.52

0.00

–7.41±25.00

0.00

 Dyspnoea

30.85±27.13

22.22

23.28±21.56

22.22

–8.24±22.57

0.00

 Cough

Symptoms (QLQ-C30)

Symptoms (QLQ-LC13)
33.76±27.47

33.33

19.58±21.28

33.33

–13.89±31.47

0.00

 Haemoptysis

1.27±6.41

0.00

0.53±4.20

0.00

–1.11±6.03

0.00

 Sore mouth

5.06±16.09

0.00

2.12±8.19

0.00

–1.11±13.68

0.00

 Dysphagia

4.64±11.61

0.00

1.59±7.16

0.00

–1.67±11.36

0.00

 Peripheral neuropathy 13.08±22.28

0.00

15.87±25.30

0.00

6.11±17.88

0.00

 Alopecia

11.69±25.80

0.00

9.52±22.74

0.00

–1.13±22.29

0.00

 Pain in the chest

21.52±28.6

0.00

5.82±17.50

0.00

–16.67±29.75

0.00

 Pain in the arm or
shoulder
 Pain in other parts

16.88±28.18

0.00

9.52±19.33

0.00

–7.22±25.37

0.00

44.00±36.42

33.33

25.27±33.43

0.00

–16.96±42.78

0.00

Values in bold represent clinically meaningful changes from baseline (ie, ≥10 point change from baseline).
Data cut-off: 27 April 2015.
QLQ-C30, 30-Item Quality of Life Questionnaire-Core; QLQ-LC13, 13-Item Quality of Life Questionnaire-lung cancer-specific module.

Symptoms and HRQoL
The completion rate for patients who undertook PRO
assessments at baseline was 90% (n=79) for both questionnaires. At the next subsequent assessment (week 6),
the completion rates were 78% (n=68) for the EORTC
QLQ-C30 and 72% (n=63) for the EORTC QLQ-LC13.
Changes from baseline values in symptoms, functioning and HRQoL scales are shown in table 1.
According to the EORTC QLQ-C30, on average,
patients at the first postbaseline visit (week 6) showed
improvements in their GHS and all five functioning
scales compared with baseline, with clinically meaningful mean changes in GHS (mean change±SD:
15.89±25.66), social functioning (11.20±23.20) and
role functioning (14.84±32.00) (table 1; figure 1A). At
Ou S-HI, et al. ESMO Open 2018;3:e000364. doi:10.1136/esmoopen-2018-000364

week 12, the change from baseline in emotional functioning subscale had reached the clinically meaningful
threshold at a mean value of 11.01±17.04 (n=54). The
initial clinically meaningful improvement in GHS from
the first assessment date was maintained during study
treatment, as the mean value remained ≥10 points above
baseline until just before the last study visit (figure 1B).
Immediate improvements postbaseline were noted
in all but one of the symptom subscale assessments
using the EORTC QLQ-C30 (figure 2A). Clinically
meaningful mean symptom reductions were seen for
fatigue (10.94±25.70), pain (–12.50±33.47), dyspnoea
(–12.17±32.96) and appetite loss (−16.67±30.28).
An improvement from baseline was also seen in
common treatment-related symptoms such as nausea and
3
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Figure 1 (A) Mean change from baseline in global health status and functional scales of the QLQ-C30 after 6 weeks of
alectinib treatment. (B) Maintenance of clinically meaningful improvement in global health status throughout the study. HRQoL,
health-related quality of life; QLQ-C30, 30-Item Quality of Life Questionnaire-Core.

vomiting, insomnia and diarrhoea. The only treatment-related symptom to worsen during alectinib treatment was
constipation (mean change: 9.90±30.68); however, this
did not reach the clinically meaningful threshold.
Analysis of the EORTC QLQ-LC13 also showed
mean improvement in all but one of the symptom

and subscale assessments (figure 2B). By the
first postbaseline assessment (6 weeks), clinically
meaningful improvement was seen in patient-reported cough (–13.89±31.47), pain in the chest
(–16.67±29.75) and pain in other parts (–16.96±42.78)
(table 1, figure 2B).
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Figure 2 Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment
according to (A) the QLQ-C30 and (B) the QLQ-LC13. QLQ-C30, 30-Item Quality of Life Questionnaire-Core; QLQ-LC13, 13Item Quality of Life Questionnaire-lung cancer-specific module.

Clinically meaningful improvement of similar magnitude was seen in the mean GHS over time in both patients
with or without CNS metastases at baseline (figure 3).
Treatment with alectinib resulted in a median time to
symptom improvement, using the composite endpoint
of cough, dyspnoea and pain in the chest, of 1.4 months
(95% CI 1.4 to 1.6; 6.1 weeks (95% CI 6.1 to 7.0 weeks)),
with more than 50% of patients showing improvement
within the first few weeks (figure 4A). The median time
to symptom deterioration, defined as being free of a
Ou S-HI, et al. ESMO Open 2018;3:e000364. doi:10.1136/esmoopen-2018-000364

clinically meaningful deterioration in cough, dyspnoea
or chest pain, was 5.1 months (95% CI 2.8 to 6.8; 22.1
weeks) using the EORTC QLQ-LC13 (figure 4B).
Relationship between best overall response, emotional
functioning and cognitive functioning
Online supplementary figure 1 shows the mean changes
from baseline in patient-reported emotional and
cognitive functioning for both responders (complete
or partial response) and non-responders over the
5
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Figure 3 Mean change from baseline in HRQoL scores for patients with and without baseline CNS metastases. Data cut-off:
27 April 2015. CNS, central nervous system; HRQoL, health-related quality of life.

66-week study period. On average, patients who were
responders generally maintained or improved their
level of emotional functioning and cognitive functioning while on treatment through week 66. Patients
who were non-responders reported either maintained
or modestly decreased scores for both functioning
scales while on treatment.
Relationship between ECOG PS and PROs
An exploratory analysis to show the relationship
between ECOG PS and baseline PRO scores was undertaken and, according to the respective items and scales
of the EORTC QLQ-C30, patients with a higher ECOG
PS (1 or 2) had worse mean symptom values at baseline for appetite loss, constipation, fatigue, nausea and
vomiting, and pain, compared with patients with an
ECOG PS of 0 (online supplementary table 1), as would
be expected (patients with an ECOG PS of 0 are by definition asymptomatic). Similarly, patients with a higher
ECOG PS had lower mean scores across all five functioning scales. With respect to the items and scales of the
EORTC QLQ-LC13, a higher ECOG PS was associated
with worse mean baseline symptom scores in dysphagia,
alopecia, pain in other parts and sore mouth, compared
with an ECOG PS of 0 (online supplementary table 1).
Figure 4 Kaplan-Meier plots of (A) time to first
improvement and (B) time to first deterioration in pain
in the chest, cough and dyspnoea, according to the 13Item Quality of Life Questionnaire-lung cancer-specific
module.
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Discussion
Alectinib has shown promising efficacy in the treatment of ALK-positive NSCLC, both systemically and
Ou S-HI, et al. ESMO Open 2018;3:e000364. doi:10.1136/esmoopen-2018-000364
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in the CNS,5–9 and is well tolerated. Additionally,
alectinib has now demonstrated significantly improved
progression-free survival over crizotinib in patients with
advanced treatment-naïve ALK+ NSCLC.9 This current
analysis is the first to demonstrate that alectinib can
both improve patient-reported symptom burden and
enhance HRQoL.
By the first postbaseline PRO assessment (week 6),
patients reported a clinically meaningful improvement
in many lung cancer symptoms (fatigue, dyspnoea,
cough, pain, chest pain, pain in other parts), suggesting
an immediate symptom benefit with treatment.
Furthermore, time-to-event analyses concerning core
lung cancer symptoms of dyspnoea, cough and chest
pain demonstrated a median time to symptom improvement of 1.4 months, which corresponds to the first
postbaseline PRO assessment. The immediate symptom
benefit with alectinib was sustained for patients on treatment; additional time-to-event analyses indicated that
the median time to symptom deterioration was approximately 5.1 months from baseline. Correspondingly, a
clinically meaningful improvement in GHS was seen
at the earliest postbaseline PRO assessment and maintained until before the last study visit, demonstrating
an early and sustained improvement in HRQoL for
alectinib-treated patients in this study. This pattern of
lung cancer symptom and HRQoL improvement was
observed in patients irrespective of the presence of CNS
metastases at baseline. A clinically meaningful improvement in loss of appetite was also seen; a recent study
by Patel et al16 demonstrated that weight gain, due to
overall improvement of appetite loss and improvement
in nausea/vomiting, can be used as an indicator of clinical benefit. This PRO finding was supported via observations of weight gain in 18.6% of patients in the North
American study (NP28761; NCT01871805) and in
12.3% of patients in the phase II global study (NP28673;
NCT018011) at the updated 2016 data cut-offs; however,
this gain could also be related to possible increases in
fluid retention.
The baseline values observed in this study were
similar to historical values reported in patients with
stage III/IV lung cancer using the EORTC QLQ-C30
questionnaire.17 The large SDs observed throughout
these analyses are common for skewed populations,
which is a limitation of the mean change score estimates; meaningful median improvements, however,
were also seen in the GHS and fatigue domains of the
EORTC QLQ-C30.
In conclusion, patients treated with alectinib in the
North American NP28761 study reported clinically
meaningful improvement in key lung cancer symptoms, patient-reported function and HRQoL while
remaining a tolerable treatment option. In the ALUR
study (NCT02604342), alectinib improved HRQoL,
functioning and symptom burden versus chemotherapy
in patients with ALK+ NSCLC after crizotinib failure
(ALUR, NCT02604342).18 Quality of life endpoints
Ou S-HI, et al. ESMO Open 2018;3:e000364. doi:10.1136/esmoopen-2018-000364

are being evaluated in two first-line phase III studies
investigating alectinib (ALEX, NCT020758409 and
J-ALEX, JapicCTI-132316).19
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